Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest CSL Limited Stories

2013-12-09 20:22:42

Data Presented at the American Society of Hematology (ASH) Annual Meeting NEW ORLEANS, Dec. 9, 2013 /PRNewswire/ -- Data presented today by CSL Behring at the 55th Annual Meeting of the American Society of Hematology (ASH) showed Kcentra(®) (Prothrombin Complex Concentrate [Human]) was superior to plasma, the current standard of care in the U.S., in adult patients taking vitamin K antagonist therapy (VKA; e.g., warfarin) who required warfarin reversal prior to an urgent surgery or...

2013-12-03 16:24:40

The global biopharmaceutical's latest corporate responsibility report offers a bird's- eye view of the company's economic, social and environmental performance. KING OF PRUSSIA, Pa., Dec. 3, 2013 /PRNewswire/ -- CSL Behring's parent company CSL Limited (ASX:CSL) reaffirms the companies' commitment to responsible business practice and sustainable development in its new corporate responsibility report - Our Corporate Responsibility 2013. The report details CSL's performance across key corporate...

2013-11-25 12:26:55

Alpha-1 is a Serious Medical Condition That Is Often Misdiagnosed as COPD or Asthma KING OF PRUSSIA, Pa., Nov. 25, 2013 /PRNewswire/ -- CSL Behring today announced the availability of DNA(1) Advanced Alpha-1 Screening(TM) (DNA(1)), a new test that aims to improve diagnosis of Alpha-1 Antitrypsin Deficiency (Alpha-1). Launched during Alpha-1 Awareness Month, DNA(1) is the only comprehensive Alpha-1 test available that identifies known and unknown clinically relevant genetic variants to help...

2013-11-20 12:27:41

Multiple presentations of study results at the American Heart Association 2013 Scientific Sessions DALLAS, Nov. 20, 2013 /PRNewswire/ -- Results of a Phase 2a trial of CSL112, sponsored by CSL Limited, demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease. The trial data for CSL112 also showed a dramatic and rapid increase in key biomarkers of reverse cholesterol transport, a process by which cholesterol is removed from...

2013-11-08 08:28:06

Responding HAE specialists agree that self-administration is advantageous to patients' time, independence and convenience BALTIMORE, Nov. 8, 2013 /PRNewswire/ -- More patients with hereditary angioedema (HAE), a rare and potentially fatal genetic disorder, are being offered and opting for self-administration therapy, according to data from a new survey being presented at the 2013 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Of the HAE treatment centers...

2013-10-15 08:31:20

CSL Plasma and CSL Behring celebrate International Plasma Awareness Week with week-long activities and the opening of a plasma center in Vancouver, Wash. KING OF PRUSSIA, Pa., Oct. 15, 2013 /PRNewswire/ -- CSL Plasma, operator of one of the largest plasma collection networks in the world and parent company CSL Behring are celebrating the contributions of donor-heroes during International Plasma Awareness Week (IPAW), October 13-20. The week-long observance, which is sponsored by the...

2013-10-03 12:25:37

MySource Offers One-Stop Access to Information About CSL Behring's Innovative Patient-Support Offerings ANAHEIM, Calif., Oct. 3, 2013 /PRNewswire/ -- People who are living with a rare and serious bleeding disorder will now have one-stop access to educational resources, financial support, and community connection programs through CSL Behring's MySource(TM) program. Launched during the National Hemophilia Foundation's (NHF) 65(th) Annual Meeting, MySource allows patients, caregivers and...

2013-09-27 12:26:11

New Hizentra Label Provides Primary Immunodeficiency Patients With the Flexibility to Self-Administer Their Treatment Less Frequently KING OF PRUSSIA, Pa., Sept. 27, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has expanded the administration options for Hizentra(®), Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency (PI). Hizentra,...

2013-09-27 00:20:39

TOKYO, Sept. 27, 2013 /PRNewswire/ -- CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and...

2013-09-26 23:02:12

Reportbuyer.com just published a new market research report: Global Intravenous Immunoglobulin (IVIg) Industry. London (PRWEB) September 26, 2013 This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these...